Aurobindo Pharma is all set to commence supplies to Europe from its China facility from April onwards. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up the production. The company has received European regulatory approvals and can initiate product supply to the market. The company expects good traction coming out of the China plant over the next 2-3 years.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
